Dapagliflozin

Patients with diabetes experienced significant improvement in endothelial function and microvascular reactivity while taking daily dapagliflozin, according to research presented at the virtual Heart in Diabetes Conference.

Lifestyle or medical therapy in prediabetes to reduce later cardiovascular events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker.

SGLT2 inhibitors could potentially target key mechanisms activated in COVID-19, increasing lipolysis, reducing glycolysis, inflammation and oxidative stress, and improving endothelial function to reduce organ damage, according to a speaker.

SGLT2 inhibitors reduce HF in patients with atherosclerotic CVD or risk factors regardless of diabetes status, but more data are needed particularly in HF with preserved ejection fraction, according to a speaker.

The SGLT2 inhibitor dapagliflozin was linked to significant reductions in worsening renal function and renal or cardiovascular death in adults with chronic kidney disease irrespective of type 2 diabetes, according to a press release.

Dapagliflozin for worsening HF was both safe and efficacious regardless of diuretic use or dose, according to findings from the DAPA-HF trial published in Circulation.

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.

New data from the DAPA-HF trial showed that dapagliflozin was associated with a 32% lower risk for new-onset type 2 diabetes among patients with heart failure. It was the top story in endocrinology last week.

Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data.

Healio and Cardiology Today have compiled a list of the top cardiology news from the month of May.